Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Bkm120
2. Nvp-bkm120
1. 944396-07-0
2. Nvp-bkm120
3. Bkm120
4. 5-(2,6-dimorpholinopyrimidin-4-yl)-4-(trifluoromethyl)pyridin-2-amine
5. Nvp-bkm-120
6. Bkm-120
7. 1202777-78-3
8. Bkm 120
9. Buparlisib (bkm120)
10. Nvp-bkm 120
11. Bkm120 (nvp-bkm120, Buparlisib)
12. 5-(2,6-dimorpholin-4-ylpyrimidin-4-yl)-4-(trifluoromethyl)pyridin-2-amine
13. Bkm-120nx
14. Bkm120-nx
15. 5-[2,6-di(morpholin-4-yl)pyrimidin-4-yl]-4-(trifluoromethyl)pyridin-2-amine
16. 0zm2z182gd
17. Chembl2017974
18. Chebi:71954
19. 944396-07-0 (free Base)
20. 2-pyridinamine,5-(2,6-di-4-morpholinyl-4-pyrimidinyl)-4-(trifluoromethyl)-
21. 5-[2,6-di(4-morpholinyl)-4-pyrimidinyl]-4-(trifluoromethyl)-2-pyridinamine.
22. Buparlisib [inn]
23. Buparlisib [usan:inn]
24. Unii-0zm2z182gd
25. Bkm 120nx
26. 5-[2,6-di(4-morpholinyl)-4-pyrimidinyl]-4-(trifluoromethyl)-2-pyridinamine
27. Sd5
28. Buparlisib; Bkm120
29. 3sd5
30. Buparlisib (usan/inn)
31. Buparlisib [usan]
32. Buparlisib [who-dd]
33. Mls006010984
34. Schembl146956
35. Gtpl7878
36. Bkm120,nvp-bkm120
37. Ammd00049
38. Bkm-120 (pi3k)
39. Dtxsid50241486
40. Ex-a189
41. Hms3295i15
42. Hms3655d16
43. Bkm120 (nvp-bkm120)
44. Bkm120 - Nvp-bkm120
45. Bdbm50380363
46. Mfcd18251596
47. Nsc754353
48. Nsc799370
49. S2247
50. Zinc43154039
51. 2-pyridinamine, 5-(2,6-di-4-morpholinyl-4-pyrimidinyl)-4-(trifluoromethyl)-
52. 5-(2,6-di-4-morpholinyl-4-pyrimidinyl)-4-(trifluoromethyl)-2-pyridinamine
53. Akos016005372
54. Am85983
55. Bcp9001011
56. Ccg-264954
57. Cs-0089
58. Db11666
59. Nsc-754353
60. Nsc-799370
61. Sb16577
62. Ncgc00262604-01
63. Ncgc00262604-08
64. Ac-32077
65. Ac-35575
66. As-40568
67. Hy-70063
68. Smr004702786
69. Db-079882
70. Ft-0755923
71. Sw218149-2
72. A25436
73. D10584
74. A892274
75. J-516601
76. Brd-k42191735-001-01-2
77. Q25100534
78. 4-(trifluoromethyl)-5-(2,6-dimorpholinopyrimidin-4-yl)pyridin-2-amine
79. 5-(2,6-di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine
80. 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine
| Molecular Weight | 410.4 g/mol |
|---|---|
| Molecular Formula | C18H21F3N6O2 |
| XLogP3 | 1.5 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 11 |
| Rotatable Bond Count | 3 |
| Exact Mass | 410.16780842 g/mol |
| Monoisotopic Mass | 410.16780842 g/mol |
| Topological Polar Surface Area | 89.6 Ų |
| Heavy Atom Count | 29 |
| Formal Charge | 0 |
| Complexity | 530 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Buparlisib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Buparlisib, including repackagers and relabelers. The FDA regulates Buparlisib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Buparlisib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Buparlisib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Buparlisib supplier is an individual or a company that provides Buparlisib active pharmaceutical ingredient (API) or Buparlisib finished formulations upon request. The Buparlisib suppliers may include Buparlisib API manufacturers, exporters, distributors and traders.
click here to find a list of Buparlisib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
Buparlisib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Buparlisib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Buparlisib GMP manufacturer or Buparlisib GMP API supplier for your needs.
A Buparlisib CoA (Certificate of Analysis) is a formal document that attests to Buparlisib's compliance with Buparlisib specifications and serves as a tool for batch-level quality control.
Buparlisib CoA mostly includes findings from lab analyses of a specific batch. For each Buparlisib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Buparlisib may be tested according to a variety of international standards, such as European Pharmacopoeia (Buparlisib EP), Buparlisib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Buparlisib USP).
LOOKING FOR A SUPPLIER?
